Overcoming AAV aggregate analysis challenges using a novel size exclusion column to determine CQAs
Sponsor
As the most widely used viral vector for gene therapies, Adeno-Associated Viruses (AAVs) present unique advantages, including their ability to enter both dividing and non-dividing cells, the absence of human viral illness, and minimal immune response triggers.
However, the complexity and size of AAVs pose challenges for their analysis. Traditional approaches struggle with their larger size, hindering comprehensive characterization crucial for ensuring the safety, efficacy, and functionality of gene therapies. This is particularly true for aggregate analysis testing, which is a critical quality attribute (CQA). This challenge accompanies others including long run times, high sample consumption where sample quantities are limited, and accurate quantitation of monomer and aggregate species.
In this webinar, Senior Research Scientist, Shilin Cheung, will review optimization of high throughput size exclusion chromatography methods using a novel 700 Å pore size SEC chemistry to reduce sample consumption and run times. Additionally, method versatility with multiple mobile phase conditions utilizing various detectors across several AAV serotypes will be explored.
- Learn how a novel 700 Å pore size SEC chemistry improves lab throughput and reduces sample consumption for AAV aggregate analysis
- Review of method optimization best practices to maximize AAV monomer/aggregate resolution
- Learn how selecting appropriate particle chemistry, pore size, and hardware improves SEC performance for AAV analysis
SPEAKERS
You might also like
Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME
Precision in production: optimizing monitoring and quality control for high-value plasmids
Advancing cell therapy: innovations in polymer-based encapsulation and delivery
Pure and simple: understanding LNP analytics for better mRNA-based drugs
